个人情况介绍、概览
邢刚，男，博士，特聘教授。2016年毕业于沈阳药科大学，获制药工程学士学位，2019年获沈阳药科大学药物化学专业硕士学位，2022年获沈阳药科大学药物化学专业博士学位。毕业后赴复旦大学进行博士后研究。2025年通过沈阳药科大学高层次人才计划引进，被聘为沈阳药科大学特聘教授。作为课题负责人主持国家自然科学基金青年项目1项，中国博士后科学基金1项，辽宁省博士科研启动基金1项，上海市科技创新行动计划项目1项，上海市人力资源和社会保障局项目1项。第一作者或者通讯作者身份在Nature Communications（1篇），Journal of Medicinal Chemistry（6篇，其中2篇封面文章），European Journal of Medicinal Chemistry（1篇）发表SCI论文10余篇。获上海市青年科技英才等荣誉称号。
人才称号、社会兼职等（限填10项）
1.沈阳市拔尖人才；
2.本溪市高层次人才；
3.《沈阳药科大学学报》青年编委；
主要研究方向（限填3项）
研究方向一：呼吸系统相关疾病的新药创制
研究方向二：新型荧光探针开发
主持、参与的科研项目（含科研获奖等情况）（限填10项）
1.国家自然科学基金青年项目，82404408，项目负责人
2.中国博士后科学基金面上项目，2023M740730，项目负责人
3.辽宁省博士科研启动基金，2025-BS-0751，项目负责人
4.上海市科技创新行动计划项目，23YF1407100，项目负责人
5.上海市人力资源和社会保障局“超级博士后”项目，2023196，项目负责人
近年来发表代表性论文(限第一作者或通讯作者，SCI须写明影响因子)：（限填10篇）
1. Gang Xing, Yucong Bi, Zhenli Li, Zhengxing Zhi, Haitao Li*, Maosheng Cheng*. Discovery, synthesis, and biological evaluation of novel quinoline-based PDE4 inhibitors with potent anti-chronic obstructive pulmonary disease activity. J Med Chem. 2026; 69: 3852-3867. (第一作者，IF:6.3)
2. Gang Xing, Zhenli Li, Zhengxing Zhi, Ce Yi, Ruiwen Zhang, Huali Yang, Yuyang Zhang, Bin Lin, Yang Liu*, Li Pan*, Maosheng Cheng*. Discovery and identification of novel 5-hydroxy-4H-benzo[1,4]oxazin-3-one derivatives as potent β2-adrenoceptor agonists through structure-based design, synthesis, and biological evaluation. J Med Chem. 2024; 67: 2986-3003. (第一作者，IF:6.8)
3. Gang Xing#, Dahong Li#, Anthony Yiu-Ho Woo, Zhengxing Zhi, Lei Ji, Ruijuan Xing, Hailiang Lv, Bin He, Hui An, Haiyan Zhao, Bin Lin, Li Pan*, Maosheng Cheng*. Discovery of a highly selective β2-adrenoceptor agonist with a 2-amino-2-phenylethanol scaffold as an oral antiasthmatic agent. J Med Chem. 2022; 65: 5514-5527. (共同第一作者，IF:7.3)
4. Gang Xing, Anthony Yiu-Ho Woo*, Li Pan; Bin Lin, Maosheng Cheng*. Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure. J Med Chem. 2020; 63: 15218-15242. (第一作者，IF:7.446)
5. Rui Wen#, Gang Xing#, Hao Li, Jianuo Yang, Hanqing Xu, Ting Wang, Xingqi Hu, Canyao Ding, Huali Yang, Jiang Zheng, Rong Zhang*, Mingyu Xia*, Yang Liu*, Maosheng Cheng*. Design, synthesis, and biological evaluation of acid-responsive bifunctional molecules with dual anti-helicobacter pylori and acid suppression activities. J Med Chem. 2026; 69: 1342-1357. (共同第一作者，IF:6.3)
6. Ting Wang, Haoyu Zhang, DihanTan, Ningyi Qin, Bohou Song, Pengfei Song, Yang Liu*, Dongmei Zhao*, Gang Xing*, Maosheng Cheng*. Discovery of Highly Selective CYP1B1 Inhibitors. J Med Chem. 2025; 68: 13089-13112. (共同通讯作者，IF:6.3)
7. Dongjuan Si#, Zhihao Dong#, Gang Xing#, Longfang Yao, Jun Lu, Min Ma, Yue Yuan, Hanqing Zhao, Biqin Dong, Cong Li, Lin Yuan*, Zhongwen Chen*, Lu Wang*. A bright and regenerative array tag with fluorogenic ligands for long-term live-cell nanoscopy and single-molecule tracking. Nat Commun. 2025; 17: 576. (共同第一作者，IF:15.7)
8. Gang Xing, Zhengxing Zhi, Ce Yi, Jitian Zou, Xuefeng Jing, Anthony Yiu-Ho Woo, Bin Lin, Li Pan*, Yuyang Zhang*, Maosheng Cheng*. 8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study. Eur J Med Chem. 2021; 224: 113697. (第一作者，IF:7.088)
9. Gang Xing, Ce Yi, Peiyuan Dou, Zhengxing Zhi, Bin Lin*, Maosheng Cheng*. Recent progress in the development of β2 adrenergic receptor agonists: a patent review (2015-2020). Expert Opin Ther Pat. 2021; 31: 239-246. (第一作者，IF:6.714)
10. Gang Xing, Li Pan, Ce Yi, Xiaoran Li, Xinyue Ge, Ying Zhao, Yichuang Liu, Jinyan Li, Anthony Woo, Bin Lin, Yuyang Zhang*, Maosheng Cheng*. Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2019; 27: 2306-2314. (第一作者，IF:3.073)